The US Food and Drug Administration (FDA) has expanded the indication for tbo-filgrastim (Granix, Teva), now allowing it to be self-administered by patients and their caregivers. Tbo-filgrastim, a ...
The combination therapy is the first FDA approved for the mobilization of hematopoietic stem cells prior to autologous transplantation in patients with multiple myeloma. The FDA approved motixafortide ...
The FDA has approved Aphexda plus filgrastim for the mobilization of hematopoietic stem cells in patients with multiple myeloma. The Food and Drug Administration (FDA) has approved Aphexda ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback